1. Academic Validation
  2. Property-based optimisation of PROTACs

Property-based optimisation of PROTACs

  • RSC Med Chem. 2024 Nov 7. doi: 10.1039/d4md00769g.
James S Scott 1 Iacovos N Michaelides 2 Markus Schade 1
Affiliations

Affiliations

  • 1 Oncology R&D, AstraZeneca 1 Francis Crick Avenue Cambridge CB2 0AA UK jamie.scott@astrazeneca.com.
  • 2 Discovery Sciences, AstraZeneca 1 Francis Crick Avenue Cambridge CB2 0AA UK.
Abstract

PROTACs are an emerging therapeutic approach towards targeted protein degradation. This article examines the leading examples of this modality that are in clinical development through the prism of their physicochemical properties. In particular, the optimisation of the various components of PROTACs together with the difficulties faced by medicinal chemists seeking to achieve oral bioavailability in this challenging space are outlined. Guidance, opinion and advice based on the authors' own experiences in this area are offered in the hope this may be useful to Others working in this fascinating frontier of drug discovery.

Figures
Products